See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. In 2025, biotechnology stocks had their best year since the COVID-19 ...
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 by 9 percentage ...
The Fight of Our Lives highlights biotech’s impact on patient lives in both the short- and long-term, urging continued ...
The United States is at risk of losing one of the most important technology races of the 21st century: biotechnology. A 2025 report from a bipartisan, congressionally chartered commission warns that ...
24/7 Wall St. on MSN
LABU could rip higher if biotech finally gets its long-awaited breakout
Quick Read Direxion Daily S&P Biotech Bull 3X Shares (LABU) delivered 235% returns over the past year versus 65% for the ...
Forbes contributors publish independent expert analyses and insights. I write about finance, innovation, climate and sustainability Europe’s next wave of biotech innovation could determine how the ...
Slow rolling chaos at the FDA and its effects on drug approvals. How to think about risk when investing in biotech. A review of results from DNA researcher Twist Bioscience. Don't wait! Be sure to get ...
Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500. Private investment in longevity science doubled in 2024, highlighting growing interest in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results